Patents Assigned to United States of America, as represented by the Secretary, Department of Health and Human Services
  • Antibodies and methods for the diagnosis and treatment of Epstein Barr Virus infection
    Patent number: 11926656
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 12, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
  • Coronary sinus mitral valve annuloplasty procedure and coronary artery and myocardial protection device
    Patent number: 11925558
    Abstract: Devices and methods are disclosed for the treatment or repair of regurgitant cardiac valves, such as a mitral valve. An annuloplasty device can be placed in the coronary sinus to reshape the mitral valve and reduce mitral valve regurgitation. A protective device can be placed between the annuloplasty device and an underlying coronary artery to inhibit compression of the underlying coronary artery by the annuloplasty device in the coronary sinus. In addition, the protective device can inhibit compression of the coronary artery from inside the heart, such as from a prosthetic mitral valve that exerts radially outward pressure toward the coronary artery. The annuloplasty device can also create an artificial inner ridge or retaining feature projecting into the native mitral valve region to help secure a prosthetic mitral valve.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: March 12, 2024
    Assignee: The United States of America, As Represented By The Secretary, Department of Health and Human Services
    Inventors: June-Hong Kim, Robert J. Lederman, Ozgur Kocaturk
  • Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
    Patent number: 11918638
    Abstract: Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype in which the native positions of the NS1 and/or NS2 genes in the RSV genome are shifted to a higher position, that is at positions that are more distal to the promoter. The changes in the gene positions may be present in combination with mutations at other loci to achieve desired levels of attenuation and immunogenicity. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: March 5, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Thomas Charles McCarty
  • High-resolution cerebrospinal fluid-suppressed T2*-weighted magnetic resonance imaging of cortical lesions
    Patent number: 11921181
    Abstract: Provided herein are methods and systems for high-resolution, cerebrospinal fluid-suppressed T2*-weighted magnetic resonance imaging of cortical lesions.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: March 5, 2024
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Daniel Salo Reich, Erin Savner Beck, Govind Nair, Neville Dali Gai
  • Methods and compositions for inducing protective immunity against filovirus infection
    Patent number: 11918639
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: March 5, 2024
    Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human Service
    Inventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
  • Methods of preparing anti-human papillomavirus antigen T cells
    Patent number: 11918640
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: June 13, 2022
    Date of Patent: March 5, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Methods for the detection of cervical cancer and cervical intraepithelial neoplasia
    Patent number: 11905564
    Abstract: Described herein are biomarkers for HPV-associated pre-cancers and cancers such as cervical cancer and cervical intraepithelial neoplasia. The RNA binding protein (RBP) and long-noncoding RNA (lnc-RNA) biomarkers can be detected and used to diagnose HPV-associated pre-cancers and cancers. In addition, early diagnosis of HPV-associated pre-cancers and cancers can facilitate therapeutic intervention in patients, particularly in the pre-cancer stage which can delay or prevent progression to cancer.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: February 20, 2024
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Zhi-Ming Zheng, Junfen Xu, Jun Zhu, Yanqin Yang, Xiaohong Wang
  • Kits and methods to distinguish false labor and true labor
    Patent number: 11906528
    Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: February 20, 2024
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Nanoparticle-hydrogel composite for nucleic acid molecule delivery
    Patent number: 11904057
    Abstract: This disclosure provides novel peptide hydrogels containing encapsulated nanoparticles comprising nucleic acid molecules (such as miRNA) that can undergo multiple gel-to-solution (gel-sol) and solution-to-gel (sol-gel) phase transitions, and their use, such as for controlled delivery of nucleic acid molecules to a subject.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: February 20, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Joel Schneider, Poulami Majumder, Chuong Hoang, Anand Singh
  • Recombinant RSV G proteins and their use
    Patent number: 11905313
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: February 20, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services.
    Inventor: Surender Khurana
  • Methods for the detection of tau protein aggregates
    Patent number: 11906530
    Abstract: Methods are disclosed herein for determining whether a subject has a Tauopathy, such as Pick disease, Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or argyrophilic grain disease (AGD). These methods utilize an amyloid seeding assay.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 20, 2024
    Assignee: The United States of America, as represented by the Secretary Department of Health and Human Services
    Inventors: Byron Winslow Caughey, Eri Saijo, Allison Lindsey Kraus, Michael Anthony Metrick, II
  • Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
    Patent number: 11897845
    Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: February 13, 2024
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
  • In vitro generation of thymic organoid from human pluripotent stem cells
    Patent number: 11898166
    Abstract: Disclosed are methods of preparing thymic organoids according to embodiments of the invention. Also disclosed are methods of preparing thymic emigrant cells in vitro, according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e g., cancer.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: February 13, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Raul E. Vizcardo, Nicholas P. Restifo
  • Anti-KRAS-G12D T cell receptors
    Patent number: 11897933
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: February 13, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders
    Patent number: 11897875
    Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: February 13, 2024
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Scott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
  • Methods of isolating neoantigen-specific T cell receptor sequences
    Patent number: 11898207
    Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 13, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Yong-Chen Lu, Peter Fitzgerald, Zhili Zheng, Steven A. Rosenberg
  • SURGICAL TOOL AND METHOD FOR SOFT OCULAR TISSUE TRANSPLANTATION
    Publication number: 20240041650
    Abstract: Disclosed are devices and methods for delivering a sheet of tissue into the eye in such a way that damage to the tissue is minimized, damage to the eye during insertion and manipulation of the tissue is minimized, and the tissue is released and delivered in a precise and controlled fashion.
    Type: Application
    Filed: August 14, 2023
    Publication date: February 8, 2024
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: Arvydas Maminishkis
  • Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders
    Patent number: 11890340
    Abstract: Disclosed herein are methods of treating or preventing a lung disorder comprising administering to a subject a composition comprising an agent that modulates activity and/or expression of Epithelial Membrane Protein 2 (EMP2) in an amount effective to treat or prevent the lung disorder and compositions useful in such for methods.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: February 6, 2024
    Assignee: The United States of America as Represented By The Secretary of the Department of Health and Human Services
    Inventors: Michael Brian Fessler, Carmen J. Williams, Wan-Chi Lin
  • T-cells modified to overexpress PHF19
    Patent number: 11883431
    Abstract: Provided is a mammalian T cell modified to express the Phf19 at a level that is higher than the level of Phf19 expressed by a T cell that has not been modified to express Phf19. Provided is a genetically-modified mammalian T cell comprising a genetic expression vector comprising (a) virally-, bacterially-, or both virally- and bacterially-derived genetic sequences and (b) a genetic sequence encoding Phf19, whereby the genetic sequence encoding Phf19 within the vector is expressed within the T cell. Pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells by epigenetic reprogramming are also provided.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: January 30, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Yun Ji, Luca Gattinoni
  • KITS AND METHODS FOR PREDICTION AND TREATMENT OF PREECLAMPSIA
    Publication number: 20240027470
    Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.
    Type: Application
    Filed: October 6, 2023
    Publication date: January 25, 2024
    Applicants: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero